Rapport Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

RAPP$25.96-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · Total
	Shares	Amount	Capital	Income (Loss)	Deficit	Stockholders’ Equity
Balance at December 31, 2025	47,772,567	$48	$719,287	$546	$(235,228)	$484,653
Stock-based compensation expense	—	—	6,963	—	—	6,963
Issuance of common stock upon exercise of stock options	80,867	—	809	—	—	809
Vesting of restricted stock units	6,994	—	—	—	—	—
Repurchase of unvested restricted common stock	(52,975)	—	(5)	—	—	(5)
Net loss	—	—	—	—	(19,857)	(19,857)
Change in unrealized gain (loss) on investments, net of tax	—	—	—	(1,051)	—	(1,051)
Balance at March 31, 2026	47,807,453	$48	$727,054	$(505)	$(255,085)	$471,512
Stock-based compensation expense	—	—	7,202	—	—	7,202
Issuance of common stock upon exercise of stock options	147,626	—	1,592	—	—	1,592
Net loss	—	—	—	—	(56,615)	(56,615)
Change in unrealized gain (loss) on investments, net of tax	—	—	—	(765)	—	(765)
Balance at June 30, 2026	47,955,079	$48	$735,848	$(1,270)	$(311,700)	$422,926
Stock-based compensation expense	—	—	7,634	—	—	7,634
Issuance of common stock upon exercise of stock options	133,334	—	1,710	—	—	1,710
Net loss	—	—	—	—	(40,235)	(40,235)
Change in unrealized gain (loss) on investments, net of tax	—	—	—	(845)	—	(845)
Balance at September 30, 2026	48,088,413	$48	$745,192	$(2,115)	$(351,935)	$391,190

Condensed Consolidated Statement of Stockholders’ Equity

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · Total
Shares · Amount · Capital · Income (Loss) · Deficit · Stockholders’ Equity
Balance at December 31, 2024	36,580,202	$37	$429,657	$(522)	$(123,745)		$305,427
Stock-based compensation expense	—	—	4,040	—	—		4,040
Issuance of common stock upon exercise of stock options	3,240	—	6	—	—		6
Repurchase of unvested restricted common stock	(86,008)	—	(1)	—	—		(1)
Net loss	—	—	—	—	(24,063)		(24,063)
Change in unrealized gain (loss) on investments, net of tax	—	—	—	427	—		427
Balance at March 31, 2025	36,497,434	$37	$433,702	$(95)	$(147,808)		$285,836
Stock-based compensation expense	—	—	4,389	—	—		4,389
Issuance of common stock upon exercise of stock options	243	—	—	—	—		—
Net loss	—	—	—	—	(26,732)		(26,732)
Change in unrealized gain (loss) on investments, net of tax	—	—	—	19	—		19
Balance at June 30, 2025	36,497,677	$37	$438,091	$(76)	$(174,540)		$263,512
Issuance of common stock from underwritten public offering, net of issuance costs of $18,061	11,057,692	11	269,428	—		269,439
Stock-based compensation expense	—	—	4,735	—		4,735
Issuance of common stock upon exercise of stock options	94,847	—	635	—		635
Net loss	—	—	—	—	(26,925)		(26,925)
Change in unrealized gain (loss) on investments, net of tax	—	—	—	221		221
Balance at September 30, 2025	47,650,216	$48	$712,889	$145	$(201,465)		$511,617

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.